Aronora is Revolutionizing Blood Clot Treatment with Groundbreaking Innovations

Aronora co-founder and CEO Dr. Erik Tucker has been elected as Fellow of the National Academy of Inventors (NAI)

Presentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation

Presentation to include clinical data from Aronora's phase 2 study of AB002, a first-in-class protein C activator enzyme that is being developed for the treatment and prevention of thrombotic and inflammatory diseases.

AB023 reduces dialyzer clotting compared to placebo during heparin-free dialysis, and continues to be safe and well tolerated

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.

Enzyme that selectively targets blood clots has received FDA Fast Track designation, allowing for expedited clinical development